Quantcast
Last updated on April 24, 2014 at 12:40 EDT

Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society

June 28, 2011

TSX Exchange Symbol: RVX

CALGARY, June 28, 2011 /PRNewswire/ – Resverlogix Corp. (“Resverlogix”)
(TSX:RVX) announces today the presentation of additional new findings
arising from analysis of data gathered in the Phase 2 ASSERT trial at
the annual meeting of the European Atherosclerosis Society (EAS) in
Gothenburg, Sweden.  The EAS is a prestigious meeting that brings
together both clinicians and scientists to share new knowledge in the
battle against atherosclerosis.  At the EAS, there were two
presentations co-authored by prominent scientists from Resverlogix’s
Clinical Steering Committee.

Resverlogix’s previous studies have demonstrated RVX-208 to be an orally
active small molecules that raises Apolipoprotein A-I (apoA-I)
production.  In the recently completed ASSERT trial, Resverlogix
illustrated that RVX-208 enhanced biomarkers of reverse cholesterol
transport (RCT) in keeping with its unique mechanism of action.  The
on-going analysis of the ASSERT data yielded new findings that formed
the substance of an EAS presentation entitled “Anti-Inflammatory
Effects of a Novel Inducer of Apolipoprotein A-I Synthesis: Insights
from the ASSERT Study” showing the potential role of RVX-208 in
lowering hsCRP, a well-known biomarker of inflammation which is an
important process in the pathogenesis of atherosclerosis.

Dr. Jan Johansson, Resverlogix’s Senior Vice President of Medical
Affairs, commented, “This observation is intriguing because it begins
to shine a light on the actions of RVX-208 that may extend beyond the
production of apoA-I.”

A second EAS presentation entitled “Increasing Circulating Concentration
of All HDL Particle Subclasses in Hyper-Responders to Apolipoprotein
A-I Induction: Insights from the ASSERT Study” emphasized a unique
mechanism by which RVX-208 augments RCT, a pathway for clearing
cholesterol from the body.  Enhanced activity of this pathway is
believed to not only stabilize, but possibly regress, atherosclerosis
within coronary vessels.  Based on this information, Dr. Johansson
stated, “We now know the characteristics of a large high-risk patient
population in whom significant benefit may be gained from the actions
of RVX-208.”

Mr. Don McCaffrey, President & CEO of Resverlogix, continued, “Adding
these new learnings to other observations from ASSERT underscores the
rationale for ASSURE, a Phase 2b trial of RVX-208 in which
atherosclerosis regression as determined by intravascular ultrasound
(IVUS) and biomarkers of reverse cholesterol transport will be the
measured over a 26 week period. We will continue to learn from these
and additional findings from ASSERT so that we may apply this knowledge
in the design of clinical trials which will target patient populations
who have the greatest need.”

About RVX-208
RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising
emerging drugs in the treatment of atherosclerosis. Apolipoprotein A-I
(apoA-I), the main component of high-density lipoprotein (HDL),
represents the body’s natural defense system against atherosclerosis by
mediating reverse cholesterol transport (RCT), i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver
for processing. To the Company’s knowledge RVX-208 is the only orally
active small molecule that selectively stimulates apoA-I production to
increase levels of HDL. The use of this approach will enhance HDL
functionality in mediating RCT, a pathway by which cholesterol that has
accumulated in atheroma within the arterial wall can be transported to
the liver for excretion, thus reducing or preventing atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas(TM) PR program is the
Company’s primary focus which is to develop novel small molecules that
enhance apoA-1 production. These vital therapies are focused to address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Alzheimer’s disease, Peripheral Artery Disease
and other vascular disorders. Resverlogix Corp.’s common shares trade
on the Toronto Stock Exchange (TSX:RVX). For further information please
visit www.resverlogix.com.

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, including our
statements with respect to research, development and commercialization
of novel therapeutics that reduce the risk of cardiovascular diseases
including atherosclerosis, diabetes, Alzheimer’s disease, Peripheral
Artery Disease and other vascular disorders that are not based on
historical fact, including without limitation statements containing the
words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”,
“expects”, “continue”, “estimate”, “forecasts” and other similar
expressions. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown
risks and uncertainties including but not limited to those risk factors
discussed in the Company’s Annual Information Form and January 31, 2011
MD&A which are incorporated herein by reference and other documents we
file from time to time with securities authorities, which are available
through SEDAR at
www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


Source: newswire